JC01 Rec'd PCT/PTO 08 AVG 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

O P P ANGLETTAL			Application Number		10/532,406		1			
O FRANSMITTAL FORM			Filing Date		April 22, 2005		\exists			
			First Named Invent	tor	Plowman		ヿ			
			Art Unit	-			ヿ			
(6 the user 10 all correspondence after initial filing)			Examiner Name				┨			
Total Number of Pages in This Submission 34			Attorney Docket Nu	umber	EX03-079	C-US	フ			
ENCLOSURES (check all that apply)										
☐ Fee Transmittal Form ☐ Drawing(s						owance Communication to TC	\Box			
Fee Attached	□Lio	Licensing-related Papers				Communication to Board				
		tition		•		eals and Interferences Communication to TC	.			
Amendment / Reply					(Appeal Notice, Brief, Reply Brief)					
After Final		Petition to Convert to a Provisional Application		Propriet	ary Information					
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address			Status L	etter				
Extension of Time Reque	est Te	Terminal Disclaimer			nclosure(s) dentify below):					
		Request for Refund			Return Rece	eipt Postcard	ı			
Express Abandonment R	equest CC	CD, Number of CD(s)			•					
Information Disclosure St	atement [☐ Landscape Table on CD			•		:			
Certified Copy of Priority Document(s)	Rema	Remarks								
Reply to Missing Parts/										
Incomplete Application										
Reply to Missing Par under 37 CFR1.52 o										
							_			
F:			APPLICANT, ATTOR	KNEY, OI	RAGENT	,	ᅱ			
Firm	Exelixis	, Inc.								
Signature		H	70m							
Printed Name Laleh Sha		hayestel	ayesteh							
Date August 5, 2005		5, 2005		Reg. No.	47,937					
	CERT	IFICA	TE OF TRANSMISS	ION/MAII	LING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.										
Signature	XMM	2-								
Typed or printed name Laleh Shayesteh					Date	August 5, 2005				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Plowman et al.

Application No.: 10/532,406

Filed: April 22, 2005

For: MAPK7 AS MODIFIER OF

BRANCHING MORPHOGENESIS

AND METHODS OF USE

Confirmation No.: 5784

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-079C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In accordance with 37 C.F.R §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with 37 C.F.R §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: August 5, 2005

Laleh Shayesteh Reg. No. 47,937

Tel: (650) 837-8180; Fax: (650) 837-8234

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/532,406 INFORMATION DISCLOSURE Filing Date 22 April 2005 STATEMENT BY APPLICANT First Named Inventor Plowman Art Unit (Use as many sheets as necessary) Examiner Name Sheet of I Attomey Docket Number EX03-079C-US

	· · · · · ·	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	Carvajal-Vergara,X., et al. Homo sapiens mitogen-activated protein kinase 7 (MAPK7), transcript variant 3, mRNA. GI:20986496 19-JUL-2005	
	2	Purandare,S.M., et al. Homo sapiens mitogen-activated protein kinase 7 (MAPK7), mRNA. GI:4506092 31-OCT-2000	
	3	Strausberg,R. Homo sapiens, Similar to mitogen-activated protein kinase 7, clone MGC:2148 IMAGE:3009873, mRNA, complete cds. Gl:13938512 12-JUL-2001	
	4	Strausberg,R. Homo sapiens, clone MGC:3875 IMAGE:3009873, mRNA, complete cds. GI:14124937 12-JUL-2001	
	5	Strausberg,R. Homo sapiens, mitogen-activated protein kinase 7, clone MGC:15371 IMAGE:4300124, mRNA, complete cds. GI:14602940 12-JUL-2001	
•	6	NCBI Annotation Project. Homo sapiens mitogen-activated protein kinase 7 (MAPK7), mRNA. GI:20560651 13-MAY-2002	
	7	Carvajal-Vergara,X., et al. Homo sapiens mitogen-activated protein kinase 7 (MAPK7), transcript variant 1, mRNA. GI:20986500 19-JUL-2005	
	8	Carvajal-Vergara,X., et al. Homo sapiens mitogen-activated protein kinase 7 (MAPK7), transcript variant 4, mRNA. GI:20986502 19-JUL-2005	•
	9	Purandare,S.M., et al. mitogen-activated protein kinase 7; protein kinase mitogen-activated 7 (MAP kinase) [Homo sapiens]. GI:4506093 31-OCT-2000	
			•

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.